|Tested species reactivity||Many|
|Published species reactivity||Rat, Mouse, Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||SDS-denatured, native rat tyrosine hydroxylase purified from pheochromocytoma|
|Storage buffer||0.01M HEPES, pH 7.5, with 0.15M NaCl, 0.1mg/ml BSA, 50% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||1:1,000|
|Western Blot (WB)||1:1,000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
In Western blot, this antibody detects a single ~60 kDa protein representing tyrosine hydroxylase from rat brain lysates of PC-12 cells stimulated by okadaic acid. Immunohistochemical staining of TH in human brain with OPA1-04050 results in intense labeling of the dopaminergic neurons in the substantia nigra.
Store at -20°C short term, 80°C long term.
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the synthesis of the catecholamine neurotransmitters (dopamine, epinephrine, and norepinephrine). It is responsible for the conversion of L-tyrosine to L-dopa in the catecholamine synthesis pathway. In all species, catecholamine synthesis is regulated by the interaction of TH with a cofactor, tetrahydrobiopterin (BH4). BH4 binds to the TH catalytic domain, resulting in enzymatic activity. Unlike TH in non-primate species, four human TH mRNA splice variants (hTH1-hTH4) have been isolated. These variants are identical in their catalytic domain, but differ in their N-terminal, regulatory domains. Little information has been uncovered regarding the regulatory role of these isoforms in vivo.
The role of TH in the synthesis of catecholamine neurotransmitters suggests a correlation between the enzyme and a number of neuropathogenic diseases characterized by irregular catecholamine levels. Catecholamine level irregularities have been uncovered in Parkinson's disease, schizophrenia, and dystonia, as well as a variety of cardiovascular diseases.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Systemically administered neuregulin-1ß1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
OPA1-04050 was used in immunohistochemistry - free floating to assess the effects of peripherally administered Nrg1beta1 in a toxin-based mouse model of Parkinson's disease
|Depboylu C,Rösler TW,de Andrade A,Oertel WH,Höglinger GU||Journal of neurochemistry (133:590)||2015|
Transcriptional and structural plasticity of tyrosine hydroxylase expressing neurons in both striatum and nucleus accumbens following dopaminergic denervation.
OPA1-04050 was used in immunohistochemistry to use transgenic mice to investigate the regulation of tyrosine hydroxylase positive cells following prolonged dopaminergic denervation
|Depboylu C,Klietz M,Maurer L,Oertel WH,Kobayashi K,Weihe E,Höglinger GU,Schäfer MK||Journal of chemical neuroanatomy (61-62:169)||2014|
Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease.
OPA1-04050 was used in immunohistochemistry to study the roles of brain-resident microglial cells and infiltrating myeloid cells in a murine model of Parkinson's disease
|Depboylu C,Stricker S,Ghobril JP,Oertel WH,Priller J,Höglinger GU||Experimental neurology (238:183)||2012|
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.
OPA1-04050 was used in immunohistochemistry to investigate the therapeutic effect of L-type channel antagonist isradipine in mouse Parkinson disease model
|Ilijic E,Guzman JN,Surmeier DJ||Neurobiology of disease (43:364)||2011|
Changes in serotoninergic and noradrenergic descending pain pathways during painful diabetic neuropathy: the preventive action of IGF1.
OPA1-04050 was used in immunohistochemistry to investigate the effect of IGF1 on painful diabetic neuropathy
|Morgado C,Silva L,Pereira-Terra P,Tavares I||Neurobiology of disease (43:275)||2011|
Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies.
OPA1-04050 was used in immunohistochemistry to investigate the distribution of choline acetyltransferase and tyrosine hydroxylase in cholinergic and catecholaminergic neurons
|Dugger BN,Dickson DW||Acta neuropathologica (120:633)||2010|
Incidental Lewy body disease and preclinical Parkinson disease.
OPA1-04050 was used in immunohistochemistry to determine whether incidental Lewy body disease (iLBD) is associated with preclinical Parkinson disease
|DelleDonne A,Klos KJ,Fujishiro H,Ahmed Z,Parisi JE,Josephs KA,Frigerio R,Burnett M,Wszolek ZK,Uitti RJ,Ahlskog JE,Dickson DW||Archives of neurology (65:1074)||2008|